HN2008001720A - Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina - Google Patents

Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina

Info

Publication number
HN2008001720A
HN2008001720A HN2008001720A HN2008001720A HN2008001720A HN 2008001720 A HN2008001720 A HN 2008001720A HN 2008001720 A HN2008001720 A HN 2008001720A HN 2008001720 A HN2008001720 A HN 2008001720A HN 2008001720 A HN2008001720 A HN 2008001720A
Authority
HN
Honduras
Prior art keywords
replaced
vasopresine
ariltriazolonas
arilimidazolonas
receptors
Prior art date
Application number
HN2008001720A
Other languages
English (en)
Inventor
Meier Heinrich
Bender Eckhard
Bruggemeier Ulf
Flamme Ingo
Karthaus Dagmar
Kolkhof Peter
Meibom Daniel
Schneider Dirk
Voehringer Verena
Furstner Chantal
Keldenich Jorg
Lang Diter
Pook Elisabeth
Schmeck Carsten
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of HN2008001720A publication Critical patent/HN2008001720A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A NUEVAS 4-ARILIMIDAZOL-2-ONAS Y 5-ARIL-1,2,4-TRIAZOLONAS SUSTITUIDAS, A PROCEDIMIENTOS PARA SU PREPARACION, A SU USO SOLOS O EN COMBINACIONES PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES, ASI COMO A SU USO PARA LA PREPARACION DE FARMACOS PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES, PARTICULARMENTE PARA EL TRATAMIENTO Y/O LA PREVENCION DE ENFERMEDADES CARDIOVASCULARES.
HN2008001720A 2006-05-23 2008-11-21 Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina HN2008001720A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006024024A DE102006024024A1 (de) 2006-05-23 2006-05-23 Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung

Publications (1)

Publication Number Publication Date
HN2008001720A true HN2008001720A (es) 2009-06-10

Family

ID=38353593

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2008001720A HN2008001720A (es) 2006-05-23 2008-11-21 Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina

Country Status (30)

Country Link
US (2) US8084481B2 (es)
EP (1) EP2027096B8 (es)
JP (1) JP5247684B2 (es)
KR (1) KR101426574B1 (es)
CN (1) CN101495458B (es)
AR (1) AR061114A1 (es)
AU (1) AU2007253572B9 (es)
BR (1) BRPI0711975A2 (es)
CA (1) CA2652834C (es)
DE (1) DE102006024024A1 (es)
DK (1) DK2027096T3 (es)
DO (1) DOP2007000102A (es)
EC (1) ECSP088904A (es)
ES (1) ES2385606T3 (es)
GT (1) GT200800250A (es)
HK (1) HK1136820A1 (es)
HN (1) HN2008001720A (es)
IL (1) IL195142A (es)
MA (1) MA30500B1 (es)
MX (1) MX2008014797A (es)
PE (1) PE20080706A1 (es)
PL (1) PL2027096T3 (es)
PT (1) PT2027096E (es)
RU (1) RU2460724C2 (es)
SV (1) SV2009003098A (es)
TN (1) TNSN08443A1 (es)
TW (1) TW200817336A (es)
UY (1) UY30364A1 (es)
WO (1) WO2007134862A1 (es)
ZA (1) ZA200809860B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
US20100093701A1 (en) * 2008-10-10 2010-04-15 Bruce Damiano Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
DE102008060967A1 (de) * 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102009028929A1 (de) * 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EP2539326B1 (de) 2010-02-27 2017-05-03 Bayer Intellectual Property GmbH Bis-arylverknüpfte aryltriazolone und ihre verwendung
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
AU2011308403B2 (en) * 2010-10-01 2014-08-21 Taisho Pharmaceutical Co., Ltd. 1,2,4-triazolone derivative
CN102260154A (zh) * 2011-06-10 2011-11-30 南通职业大学 一种医药中间体α-溴代对氯苯丙酮的制备方法
CN102875499B (zh) * 2011-07-12 2015-08-19 天津药明康德新药开发有限公司 3-氨甲基氧杂环丁烷及其有机酸盐的制备方法
KR102022716B1 (ko) * 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
ES2568882T3 (es) * 2011-10-27 2016-05-05 Taisho Pharmaceutical Co., Ltd. Derivado de azol
BR112014010228B1 (pt) 2011-10-28 2020-09-29 Lumena Pharmaceuticals Llc Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
PL2771003T3 (pl) 2011-10-28 2017-10-31 Lumena Pharmaceuticals Llc Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby
BR112015023646A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
RU2015139732A (ru) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
JP6387669B2 (ja) * 2013-04-26 2018-09-12 大正製薬株式会社 アゾール誘導体を含有する医薬
US10392381B2 (en) * 2014-07-18 2019-08-27 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
AU2015342017B2 (en) 2014-11-03 2020-02-06 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
GB201504763D0 (en) * 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
EP3452457B1 (en) * 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
EP3740236A1 (de) 2018-01-16 2020-11-25 Bayer Aktiengesellschaft Unterstützung bei der behandlung von herzinsuffizienz
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
WO2023041422A1 (en) 2021-09-20 2023-03-23 Basf Se Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE69024556T2 (de) 1989-07-28 1996-10-17 Merck & Co Inc Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IT1251488B (it) 1991-09-17 1995-05-15 Mini Ricerca Scient Tecnolog Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
RU2116304C1 (ru) * 1992-04-28 1998-07-27 Такеда Кемикал Индастриз, Лтд. Производные азола, способ их получения, фармацевтическая композиция
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO1999031099A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
AU2004221891B2 (en) * 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
KR20060066141A (ko) 2003-06-27 2006-06-15 버글린 코퍼레이션 오브 워싱턴 사과 및 연한 코아를 가지거나 피트를 가진 다른 과일들을작은 응력을 가지고 정확하게 코아제거하고슬라이스절단하기 위한 기계
WO2005007112A2 (en) 2003-07-16 2005-01-27 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20070281937A1 (en) 2004-03-08 2007-12-06 Robert Zelle Ion Channel Modulators
AU2005221128A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
EP1722788A4 (en) 2004-03-08 2008-02-13 Wyeth Corp MODULATORS OF IONIC CHANNELS
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
WO2008052031A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung

Also Published As

Publication number Publication date
JP5247684B2 (ja) 2013-07-24
MA30500B1 (fr) 2009-06-01
KR101426574B1 (ko) 2014-08-06
ECSP088904A (es) 2008-12-30
TW200817336A (en) 2008-04-16
DOP2007000102A (es) 2007-12-31
CA2652834A1 (en) 2007-11-29
UY30364A1 (es) 2008-01-02
CA2652834C (en) 2015-01-27
IL195142A0 (en) 2009-09-22
EP2027096A1 (de) 2009-02-25
HK1136820A1 (en) 2010-07-09
SV2009003098A (es) 2009-04-28
CN101495458A (zh) 2009-07-29
GT200800250A (es) 2009-09-14
US8084481B2 (en) 2011-12-27
KR20090014214A (ko) 2009-02-06
US20130005704A1 (en) 2013-01-03
DE102006024024A1 (de) 2007-11-29
PT2027096E (pt) 2012-07-12
AU2007253572B2 (en) 2013-06-20
AU2007253572A1 (en) 2007-11-29
AU2007253572B9 (en) 2013-07-25
ES2385606T8 (es) 2013-05-14
DK2027096T3 (da) 2012-09-10
PE20080706A1 (es) 2008-08-07
ES2385606T3 (es) 2012-07-27
EP2027096B8 (de) 2012-09-26
PL2027096T3 (pl) 2012-10-31
IL195142A (en) 2013-07-31
CN101495458B (zh) 2014-01-29
EP2027096B1 (de) 2012-05-23
ZA200809860B (en) 2010-02-24
US20090312381A1 (en) 2009-12-17
WO2007134862A1 (de) 2007-11-29
MX2008014797A (es) 2008-12-02
RU2008150598A (ru) 2010-06-27
TNSN08443A1 (en) 2010-04-14
RU2460724C2 (ru) 2012-09-10
AR061114A1 (es) 2008-08-06
JP2009537581A (ja) 2009-10-29
BRPI0711975A2 (pt) 2012-02-22

Similar Documents

Publication Publication Date Title
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
HN2009000784A (es) Dihidropirazolonas sustituidas
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CR11472A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2011002835A1 (es) Compuestos derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para tratar dolores agudos o cronicos de tipos neurogeno, asociados a enfermedades inflamatorias, entre otros.
UY31922A (es) Compuestos
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
UY29417A1 (es) Agentes endoparasiticidas
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
ECSP10010711A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
CL2009000317A1 (es) Compuestos derivados de 3-alquil-piperazina sustituida; composicion farmaceutica; y su uso en el tratamiento de la depresion y ansiedad.